More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

Bayer’s completion of its $63-billion acquisition of Monsanto, an agrochemical and seed company, fortifies the company’s plan of becoming a pure-play life-sciences company focused on pharmaceuticals, crop science, consumer healthcare, and animal...

In 2017, the FDA approved a record 1,027 abbreviated new drug applications, 843 of which were fully approved, and is working to further facilitate generic-drug development and approval. Reauthorization of the Generic Drug User Fee Amendments...

Fresh from the annual meeting of the American Society of Clinical Oncology in Chicago where pharmaceutical companies highlighted their pipelines and products, what is the outlook for the cancer-drug market, the largest therapeutic area in the...

Fortune released its annual list of the Fortune 500 companies, which rank the companies in the US with the largest revenues. So how did pharmaceutical companies and suppliers score in the 2017 rankings? Johnson & Johnson, the pharmaceutical,...

How can pharmaceutical companies and suppliers best partner to achieve cost-efficiencies and drive value? A preview of DCAT Sharp Sourcing, to be held June 26, highlights best practices. The program features collaborative approaches with insight...

Takeda Pharmaceutical’s proposed $62-billion acquisition of Shire provides Takeda with geographic and product diversification. So what would a combined Takeda/Shire be? The acquisition of Shire would strengthen Takeda’s position in markets outside...

Small molecules still dominate late-stage pipelines and remain significant in early-stage development as well. So how does that translate to contract manufacturers of advanced intermediates and small-molecule active pharmaceutical ingredients...